The FDA has approved the targeted therapeutic loncastuximab tesirine-lpyl to treat certain adult patients with large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta) to...
The FDA has granted accelerated approval to an immunotherapy to treat certain adult patients with endometrial cancer that tests positive for a specific biomarker. The U.S. Food and Drug Administration (FDA) has granted accelerated...
Stool-based tests were favored over colonoscopy for colorectal cancer screening, according to research published in the AACR journal Cancer Prevention Research.
The FDA has approved an immunotherapeutic in combination with chemotherapy to treat certain patients with gastric cancer, gastroesophageal junction cancer, and a common form of esophageal cancer. The U.S. Food and Drug Administration (FDA)...
Scientists discussed the mechanisms of chemotherapy-related cognitive impairment at a session dedicated to symptom science at the AACR Annual Meeting 2021.
The FDA granted accelerated approval to the targeted therapeutic sacituzumab govitecan to treat certain patients with the most common form of bladder cancer. The U.S. Food and Drug Administration (FDA) recently granted accelerated approval...
Immunotherapy has revolutionized cancer treatment over the past decade, providing potentially lifesaving therapies to many patients who otherwise would have limited options. Despite its success for many patients, immunotherapy still has challenges to overcome. Fortunately, novel strategies to improve the efficacy...
The immune systems of people with blood cancer respond differently to the coronavirus than the immune systems of people without cancer.
The launch of a campaign to address the decline in cancer screening rates, and more news of the week from Cancer Today.
A study indicates that people are delaying medical care until they are eligible for Medicare, and more news of the week from Cancer Today.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More